MARLEE BOGEMA: Open Payments
NPI 1396398236 · GRAND RAPIDS, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$8,207 in 111 payments from 33 companies in 2025. Trend: 2023 $2,585 · 2024 $3,278 · 2025 $8,207
Consulting: $4,266Food & beverage: $2,635Travel & lodging: $1,282Education: $23
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 20 | $4,239 |
| Janssen Biotech, Inc. | 3 | $1,212 |
| E.R. Squibb & Sons, L.L.C. | 3 | $405 |
| AstraZeneca Pharmaceuticals LP | 7 | $251 |
| GENZYME CORPORATION | 6 | $249 |
| Amgen Inc. | 2 | $221 |
| Novartis Pharmaceuticals Corporation | 16 | $186 |
| Rigel Pharmaceuticals, Inc. | 3 | $168 |
| Syndax Pharmaceuticals, Inc. | 3 | $165 |
| Merck Sharp & Dohme LLC | 5 | $142 |
Products named: LYNOZYFIC, TALVEY, IMFINZI, KISQALI, REVUFORJ, WAYRILZ, BREYANZI, REZLIDHIA.
Industry payments across MI — which companies pay providers there.
